Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05603312 · ClinicalTrials.gov registry record · Phase 1
A Double-blind Study to Evaluate the Safety of Glutamic Acid Decarboxylase Gene Transfer in Parkinson's Participants
A Phase 1 study, sponsored by MeiraGTx.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT05603312 is a Phase 1 study that has completed, run by MeiraGTx. The registered enrollment target is 14 participants.
The verdict
NCT05603312, a Phase 1 study, has completed, sponsored by MeiraGTx.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
The objective of this clinical trial was to evaluate the safety and tolerability of adeno-associated virus (AAV)-mediated delivery of glutamic acid decarboxylase (GAD) gene transfer into the subthalamic nuclei (STN) of participants with Parkinson's Disease.
Interventions
- PROCEDURE Sham Surgery
- GENETIC AAV-GAD Low Dose
- GENETIC AAV-GAD High Dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2022-10-05 |
| Est. Completion | 2024-09-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05603312
The ClinicalTrials.gov registry entry for NCT05603312 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MeiraGTx, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Sham Surgery is the first listed.
NCT05603312 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05603312 about?
NCT05603312 is a clinical study titled "A Double-blind Study to Evaluate the Safety of Glutamic Acid Decarboxylase Gene Transfer in Parkinson's Participants". The objective of this clinical trial was to evaluate the safety and tolerability of adeno-associated virus (AAV)-mediated delivery of glutamic acid decarboxylase (GAD) gene transfer into the subthalamic nuclei (STN) of participants with Parkinson's Disease.
What is the current status of trial NCT05603312?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2022-10-05. Estimated completion is 2024-09-06.
What interventions are being tested in trial NCT05603312?
The interventions under investigation include: Sham Surgery (PROCEDURE), AAV-GAD Low Dose (GENETIC), AAV-GAD High Dose (GENETIC).
Who is sponsoring clinical trial NCT05603312?
This trial is sponsored by MeiraGTx, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.